Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | AXL1717 |
Synonyms | |
Therapy Description |
AXL1717 inhibits IGF-1R, potentially leading to decreased tumor growth (PMID: 21875414). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AXL1717 | Picropodophyllin|PPP|Picropodophyllotoxin | IGF-1R Inhibitor 17 | AXL1717 (picropodophyllin) inhibits IGF-1R, potentially leading to decreased tumor growth (PMID: 21875414, PMID: 31340850). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | lung non-small cell carcinoma | not applicable | AXL1717 | Phase Ib/II | Actionable | In a Phase 1b/II trial, AXL1717 (picropodophyllin) was well tolerated and 25% (4/16) of patients diagnosed with NSCLC demonstrated a partial tumor response (PMID: 26161618). | 26161618 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01721577 | Phase Ib/II | AXL1717 | Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas | Unknown status | USA | 0 |